ABVC BIOPHARMA INC
ABVCNASDAQ🏆 #3562 by market capUS Equity
$638.44▲ $43.09 (+6.75%)
Simulated price1h—
24h▲ 6.8%
7d—
14d—
30d—
1y—
🏦Market Cap
$26M
Small Cap
📈Revenue Growth (YoY)
+56.6%
High Growth
📊Gross Margin
0.3%
Thin
💵FCF Margin
21.3%
Strong
⚖️P/S Ratio
31.6x
Expensive
Otter Score
64
Fair
No chart data available for ABVC.
Trading Snapshot
- Day Range
- $631.36 – $643.73
- 52-Week Range
- $0.88 – $3.40
- Volume
- $2.84B
- Avg Volume
- $3.17B
- Shares Outstanding
- 26.0M
- Next Earnings
- Sep 1, 2026
Fundamentals Snapshot
- Annual Revenue
- $827,231
- Last Q Revenue
- $186,858
- P/E Ratio
- —
- P/S Ratio
- 31.6x
- EPS (TTM)
- $-0.42
- Dividend Yield
- —
Why Investors Own ABVC
- ✓High-growth profile — revenue up +49.5% YoY with expanding US Equity exposure.
- ✓Healthy economics — 29% gross margin and 7% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
Revenue (TTM)
$827,231▲ +56.2% YoY
Gross Margin (TTM)
28.6%▲ +2.1% YoY
Operating Income (TTM)
$155,519▲ +56.2% YoY
Free Cash Flow (TTM)
$58,733▲ +56.2% YoY
About ABVC BIOPHARMA INC
A company profile for ABVC BIOPHARMA INC isn’t available yet — check back soon.
🦦
Otter Score Breakdown
ⓘ💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
Overall Score
Fair
64/100
Analyst Price Target
ⓘAverage Target
$829.77
▲ +30.0% Upside
High Target$906.74
Low Target$617.25
Based on 37 analysts
Latest News & Updates
🚀
CNBC·2h ago
ABVC BIOPHARMA INC tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
🛰️
CNBC·5h ago
Analysts lift ABVC price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
🌌
MarketWatch·1d ago
ABVC BIOPHARMA INC announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.